

**Amendments to the Claims**

This listing of claims will replace all prior version and listings of claims in this application.

**Listing of Claims**

1. **(previously presented)** A pharmaceutical dosage form comprising a fill material sealed in capsule shells wherein the fill material comprises (a) celecoxib and (b) sodium metabisulfite, wherein the capsule shells comprise gelatin, and wherein the sodium metabisulfite is present in a total sulfite amount sufficient to inhibit gelatin cross-linking and/or pellicle formation in the capsule shells upon storage of the dosage form.
2. **(canceled)**
3. **(previously presented)** The dosage form of claim 1 wherein the sodium metabisulfite is present in a total sulfite amount of not more than about 10% of the dosage form on a dry weight basis.
4. **(previously presented)** The dosage form of claim 1 wherein the fill material further comprises at least one pharmaceutically acceptable excipient selected from the group consisting of free radical-scavenging antioxidants, sweeteners, preservatives, wetting agents, buffering agents, flavoring agents, colorants, stabilizers, fragrances, glidants, crystallization inhibitors, adhesives, lubricants, and thickeners.
5. **(previously presented)** The dosage form of claim 1 further comprising at least one free radical-scavenging antioxidant compound selected from the group consisting of  $\alpha$ -tocopherol (vitamin E), ascorbic acid (vitamin C) and salts thereof including sodium ascorbate and ascorbic acid palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), fumaric acid and salts thereof, hypophosphorous acid, malic acid, alkyl gallates, sodium sulfite, sodium bisulfite and sodium metabisulfite.
6. **(previously presented)** The dosage form of claim 5 wherein the at least one free radical-scavenging antioxidant is present in a total antioxidant amount of about 0.01% to about 5% of the dosage form on a dry weight basis.
7. **(withdrawn)** The dosage form of claim 1 further comprising at least one sweetener compound selected from the group consisting of mannitol, propylene glycols, sodium saccharins, acesulfame Ks, neotame, and aspartame, sorbitols, sucrose, and high-fructose corn syrups.
8. **(withdrawn)** The dosage form of claim 1 wherein the fill material further comprises at least one preservative compound selected from the group consisting of benzalkonium chlorides, benzethonium chlorides, benzyl alcohols, chlorobutanols, phenols, phenylethyl alcohols, phenylmercuric nitrates, and thimerosols.

**9. (currently amended)** The dosage form of claim 1 wherein the fill material further comprises at least one surfactant selected from the group consisting of benzalkonium chloride, benzethonium chloride, cetylpyridinium chloride, dioctyl sodium sulfosuccinate, nonoxynol 9, nonoxynol 10, octoxynol 9, poloxamers, polyoxyethylene (8) caprylic/capric mono- and diglycerides (e.g., ~~Labrasol~~<sup>TM</sup> of ~~Gattefossé~~), polyoxyethylene (35) castor oil, polyoxyethylene (20) cetostearyl ether, polyoxyethylene (40) stearate, polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, propylene glycol laurate, sodium lauryl sulfate, sorbitan monolaurate, sorbitan monooleate, sorbitan monopalmitate, sorbitan monostearate, tyloxapol, and mixtures thereof.

**10. (previously presented)** The dosage form of claim 1 wherein the fill material is liquid.

**11. (withdrawn)** The dosage form of claim 1 wherein the fill material is self-emulsifying upon contact with gastric fluid.

**12. (previously presented)** The dosage form of claim 1 wherein the fill material further comprises a solvent.

**13. (previously presented)** The dosage form of claim 12 wherein the celecoxib and the sodium metabisulfite are in solution in the solvent.

**14. (previously presented)** The dosage form of claim 12 wherein the solvent is present in an amount of about 5% to about 95% of the dosage form on a dry weight basis.

**15. (previously presented)** The dosage form of claim 12 wherein the solvent comprises at least one of a glycol component and a glycol ether component.

**16. (previously presented)** The dosage form of claim 12 wherein the solvent comprises a glycol ether component having an average molecular weight of about 75 to about 1000.

**17. (previously presented)** The dosage form of claim 12 wherein the solvent comprises at least one glycol ether selected from the group consisting of ethylene glycol monomethyl ethers, ethylene glycol dimethyl ethers, ethylene glycol monoethyl ethers, ethylene glycol diethyl ethers, ethylene glycol monobutyl ethers, ethylene glycol dibutyl ethers, ethylene glycol monophenyl ethers, ethylene glycol monobenzyl ethers, ethylene glycol butylphenyl ethers, ethylene glycol terpinyl ethers, diethylene glycol monomethyl ethers, diethylene glycol dimethyl ethers, diethylene glycol monoethyl ethers, diethylene glycol diethyl ethers, diethylene glycol divinyl ethers, ethylene glycol monobutyl ethers, diethylene glycol dibutyl ethers, diethylene glycol monoisobutyl ethers, triethylene glycol dimethyl ethers,

triethylene glycol monoethyl ethers, triethylene glycol monobutyl ethers, and tetraethylene glycol dimethyl ethers.

**18. (previously presented)** The dosage form of claim 12 wherein the solvent comprises at least one glycol selected from the group consisting of propylene glycol, 1,3-butanediol and polyethylene glycols.

**19. (previously presented)** The dosage form of claim 12 wherein the solvent comprises polyethylene glycol having an average molecular weight of about 100 to about 10,000.

**20. (previously presented)** The dosage form of claim 12 further comprising at least one co-solvent selected from the group consisting of alcohols, oleic acid triglycerides, linoleic acid triglycerides, caprylic triglycerides, capric triglycerides, caprylic monoglycerides, capric monoglycerides, caprylic diglycerides, capric diglycerides, polyoxyethylene caprylic glycerides, polyoxyethylene capric glycerides, propylene glycol fatty acid esters, polyoxyethylene (35) castor oils, polyoxyethylene glyceryl trioleates, lower alkyl esters of a fatty acid, and water.

**21-23 (canceled)**

**24. (previously presented)** The dosage form of claim 1 wherein the celecoxib is present in an amount of about 10 to about 400 mg.

**25. (previously presented)** The dosage form of claim 1 wherein the capsule shells are hard gelatin capsule shells.

**26. (previously presented)** The dosage form of claim 1 wherein the capsule shells are soft gelatin capsule shells.

**27. (previously presented)** The dosage form of claim 1 wherein each of the gelatin capsule shells have a fill capacity of about 0.1 ml to about 2 ml.

**28-29 (canceled)**

**30. (previously presented)** The dosage form of claim 1 wherein the sodium metabisulfite is present in a total sulfite amount of about 0.5% to about 5% on a dry weight basis; wherein the fill material further comprises hydroxypropyl methylcellulose and/or polyethylene glycol, wherein the celecoxib is present in an amount of about 10 to about 400 mg, and wherein the capsule shells are soft gelatin capsule shells.

**31 (canceled)**